Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTU: PTX-022 in Angiokeratomas
NCT07552077Phase 2Recruiting
- Sponsor
- Palvella Therapeutics
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Modality
- Polymer-based Nanoparticles, Transdermal Patches, Hydrogel Systems
- Countries
- 1
01
Overview
A Phase 2 trial of QTORIN rapamycin in angiokeratoma, sponsored by Palvella Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
QTORIN rapamycin
03
Conditions
angiokeratoma
Beyond the preview
Go deeper on NCT07552077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552077.